F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have identified new benzimidazoles acting as serine/threonine-protein kinase SIK inhibitors reported to be useful for the treatment of rheumatoid arthritis, metabolic dysfunction-associated steatohepatitis (MASH), giant cell arteritis, primary sclerosing cholangitis, inflammatory bowel disease, atherosclerosis, type 2 diabetes and glomerulonephritis, among others.